Signal active
Bio
Hongbo Lu is an Executive Director on the Asia team. Previously, Hongbo Lu spent more than five years at Piper Jaffray & Co as an equity analyst. She led Piper's China healthcare research team and was instrumental in building the firm's brand in the Asian marketplace. Prior to her Wall Street career, Hongbo Lu spent four years in life science start-up operations and business development at Zyomyx, Inc.
Hongbo Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and a B.S./M.S. in Materials Science and Engineering from Tsinghua University in China.
Location
Palo Alto, California, United States, North America
Social
Primary Organization
1996
216
60
103
51-100
Financial Services, Venture Capital, Finance, Health Care
Jobs history
5
Rgenta Therapeutics
Board Member
Invalid date - Current
Zenas BioPharma
Board Member
2022 - Current
Visirna Therapeutics
Board Member
Invalid date - Current
Ablaze Pharmaceuticals
Board Member
Invalid date - Current
Vivo Capital
Managing Partner
2020 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Hongbo Lu is the Managing Partner at Vivo Capital, based in United States, North America. With a background in Financial Services, Hongbo Lu has a rich history of leadership and innovation. Hongbo Lu studied Ph.D Bioengineering @ University of Washington. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
10
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Apr 25, 2022 | Visirna Therapeutics | Seed Round - Visirna Therapeutics | Vivo Capital | 60.0M |
Nov 07, 2022 | Zenas BioPharma | Series B - Zenas BioPharma | Vivo Capital | 118.0M |
Nov 29, 2022 | Rgenta Therapeutics | Series A - Rgenta Therapeutics | Vivo Capital | 52.0M |
Aug 30, 2023 | Ronovo Surgical | Series B - Ronovo Surgical | Vivo Capital | 27.5M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.